Pharmacodynamic profile of prostacyclin

Vane, 1971, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nature, 231, 232 Euler US, 1934, Zur Kenntnis der pharmakologischen Wirkungen von Nativsekreten und Extrakten männlicher accessorischer Geschlectsdrüssen, Arch Exp Pathol Pharmakol, 175, 78, 10.1007/BF01861161 Bergström, 1962, Isolation of prostaglandin E1 from human seminal plasma, J Biol Chem, 237, 3005, 10.1016/S0021-9258(18)60264-9 Bergström, 1964, The enzymatic formation of prostaglandin E2 from arachidonic acid, prostaglandins and related factors, Biochim Biophys Acta, 90, 207, 10.1016/0304-4165(64)90145-X van Dorp, 1964, The biosynthesis of prostaglandins, Biochim Biophys Acta, 90, 204, 10.1016/0304-4165(64)90144-8 Moncada, 1976, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature, 263, 663, 10.1038/263663a0 Hamberg, 1975, Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides, 72, 2994 Bunting, 1976, Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation, Prostaglandins, 12, 897, 10.1016/0090-6980(76)90125-8 Moncada, 1977, Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium, Thromb Res, 11, 323, 10.1016/0049-3848(77)90185-2 Weksler, 1977, Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells, 74, 3922 MacIntyre, 1978, Localisation and stimulation of prostacyclin production in vascular cells, Nature, 271, 549, 10.1038/271549a0 Moncada, 1979, Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin, Pharmacol Rev, 30, 293 Whittle, 1980, Gastro-intestinal Mucosal Blood Flow, 180 Axelrod, 1981, Prostacyclin production by isolated adipocytes, Diabetes, 30, 163, 10.2337/diab.30.2.163 Ubatuba, 1979, The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time, Thromb Haemost, 41, 425, 10.1055/s-0038-1646791 Szczeklik, 1978, Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men, Pharmacol Res Commun, 10, 545, 10.1016/S0031-6989(78)80053-8 Aiken, 1979, Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation, Prostaglandins, 17, 483, 10.1016/0090-6980(79)90001-7 Bayer, 1979, Anti-aggregatory effect of prostacyclin (PGI2) in vivo, Br J Pharmacol, 66, 10, 10.1111/j.1476-5381.1979.tb16090.x Rosenblum, 1979, Topical prostacyclin (PGI2) inhibits platelet aggregation in pial venules of the mouse, Stroke, 10, 399, 10.1161/01.STR.10.4.399 Gorman, 1977, Modulation of human platelet adenylate cyclase by prostacyclin (PGX), Prostaglandins, 13, 377, 10.1016/0090-6980(77)90018-1 Tateson, 1977, Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets, Prostaglandins, 13, 389, 10.1016/0090-6980(77)90019-3 Kaser-Glanzmann, 1977, Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3′, 5′-cyclic monophosphate and protein kinase, Biochim Biophys Acta, 466, 429, 10.1016/0005-2736(77)90336-4 Lapetina, 1977, Cyclic adenosine 3′, 5′-monophosphate and prostacyclin inhibit membrane phospholipase activity in platelets, Biochem Biophys Res Commun, 76, 828, 10.1016/0006-291X(77)91575-3 Minkes, 1977, Cyclic adenosine 3′, 5′-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions, J Clin Invest, 59, 449, 10.1172/JCI108659 Malmsten, 1976, Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets, Biochem Biophys Res Commun, 68, 569, 10.1016/0006-291X(76)91183-9 Higgs, 1978, Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium, Prostaglandins, 16, 17, 10.1016/0090-6980(78)90197-1 Whittle, 1980, Role of prostaglandins in the defense of the gastric mucosa, Brain Res Bull, 5, 7, 10.1016/0361-9230(80)90297-X Moncada, 1982, The prostacyclin/thromboxane balance and cardiovascular disease, 83 Vane, 1983, Clinical potential of prostacyclin, Adv Prostaglandins Thromboxane, Leukot Res, 11, 449 Jugdutt, 1979, Infarct size reduction by prostacyclin after coronary occlusion in conscious dogs, Clin Res, 27, 177A Ogletree, 1979, Studies on the protective effect of prostacyclin in acute myocardial ischemia, Eur J Pharmacol, 56, 95, 10.1016/0014-2999(79)90438-2 Ribeiro, 1981, Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality, Am J Cardiol, 47, 835, 10.1016/0002-9149(81)90182-X Starnes, 1982, Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs, J Cardiovasc Pharmacol, 4, 765, 10.1097/00005344-198209000-00011 Ohlendorf, 1980, Prevention of infarction-induced decrease in circulating platelet count by prostacyclin, Thromb Res, 19, 447, 10.1016/0049-3848(80)90017-1 Demling, 1981, The effect of prostacyclin infusions on endotoxin-induced lung injury, Surgery, 89, 257 Fletcher, 1980, The effects of prostacyclin (PGI2) on endotoxin shock and endotoxin-induced platelet aggregation, Circ Shock, 7, 299 Lefer, 1980, Salutory effects of prostacyclin in endotoxin shock, Pharmacology, 21, 206, 10.1159/000137434 Araki, 1980, Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver, Am J Physiol, 238, H176 Monden, 1982, Twenty-four and 48-hour canine liver preservation by simple hypothermia with prostacyclin, Ann Surg, 196, 38, 10.1097/00000658-198207000-00009 Moncada, 1982, The use of prostacyclin for the separation and washing of human platelets from plasma, Br J Pharmacol, 75, 165P Blackwell, 1982, Prostacyclin prolongs viability of washed human platelets, Biochim Biophys Acta, 718, 60, 10.1016/0304-4165(82)90009-5 Jakschik, 1974, Profile of circulating vasoactive substances in hemorrhagic shock and their pharmacologic manipulation, J Clin Invest, 54, 842, 10.1172/JCI107824 Johnston, 1976, Effect of hemorrhagic shock on renal release of prostaglandin E, Am J Physiol, 230, 831, 10.1152/ajplegacy.1976.230.3.831 Collier, 1972, Appearance of prostaglandins in the renal venous blood of dogs in response to acute systemic hypotension produced by bleeding or endotoxin, J Physiol(Lond), 230, 19P Parratt, 1974, The effect of indomethacin on the cardiovascular and metabolic responses to E. coli endotoxin in cat, Br J Pharmacol, 50, 177, 10.1111/j.1476-5381.1974.tb08559.x Feuerstein, 1981, Effect of indomethacin on the blood pressure and plasma catecholamine responses to acute endotoxaemia, J Pharm Pharmacol, 33, 576, 10.1111/j.2042-7158.1981.tb13869.x Mózes, 1991, Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs; protective effects of indomethacin, Br J Pharmacol, 104, 691, 10.1111/j.1476-5381.1991.tb12490.x Gray, 1991, The effect of inhibitors of the l-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats, Br J Pharmacol, 103, 1218, 10.1111/j.1476-5381.1991.tb12327.x Vane, 1969, The release and fate of vaso-active hormones in the circulation, Br J Pharmacol, 35, 209, 10.1111/j.1476-5381.1969.tb07982.x Ferreira, 1971, Indomethacin and aspirin abolish prostaglandin release from the spleen, Nature (New Biol), 231, 237, 10.1038/newbio231237a0 Piper, 1971, The release of prostaglandins from lung and other tissues, Ann NY Acad Sci, 180, 363, 10.1111/j.1749-6632.1971.tb53205.x Ferreira, 1973, Some effects of inhibiting endogenous prostaglandin formation on the responses of the cat spleen, Br J Pharmacol, 47, 48, 10.1111/j.1476-5381.1973.tb08157.x Gryglewski, 1975, Prostaglandin feedback mechanism limits vasoconstrictor action of norepinephrine in perfused rabbit ear, Experientia, 31, 89, 10.1007/BF01924695 Grodzinska, 1975, Generation of prostaglandin E-like material by the guinea-pig trachea contracted by histamine, J Pharm Pharmacol, 27, 88, 10.1111/j.2042-7158.1975.tb09414.x Carlson, 1977, Effect of a glucocorticoid on prostaglandin production during simulated shock conditions in the perfused cat liver, Biochem Pharmacol, 26, 1463, 10.1016/0006-2952(77)90416-6 Lewis, 1976, Inhibition of prostaglandin release by anti-inflammatory steroids, Adv Prostaglandin Thromboxane Res, 1, 121 Gryglewski, 1975, Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pig, Prostaglandins, 10, 343, 10.1016/S0090-6980(75)80087-6 Flower, 1976, Some properties of rabbit aorta contracting substance-releasing factor (RCS-RF), Br J Pharmacol, 57, 461P Korbut, 1978, The influence of hydrocortisone and indomethacin on the release of prostaglandin-like substances during circulatory shock in cats, which was induced by an intravenous administration of rabbit blood, Pharmacol Res Commun, 10, 371, 10.1016/S0031-6989(78)80031-9 1983 Nawroth, 1984, Prostacyclin production by perturbed bovine aortic endothelial cells in culture, Blood, 64, 801, 10.1182/blood.V64.4.801.801 Suttorp, 1987, Endotoxin alters arachidonate metabolism in pulmonary endothelial cells, Am J Physiol, 253, C384, 10.1152/ajpcell.1987.253.3.C384 Fu, 1990, The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes, J Biol Chem, 265, 16737, 10.1016/S0021-9258(17)44821-6 O'Sullivan, 1992, Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase, J Biol Chem, 267, 14547, 10.1016/S0021-9258(18)42073-X Miossec, 1986, Production of interleukin 1 by human endothelial cells, J Immunol, 136, 2486, 10.4049/jimmunol.136.7.2486 Dinarello, 1988, Biology of interleukin 1, FASEB J, 2, 108, 10.1096/fasebj.2.2.3277884 Okusawa, 1988, Interleukin-1 induces a shock-like state in rabbits, J Clin Invest, 81, 1162, 10.1172/JCI113431 Rossi, 1985, Prostacyclin synthesis induced in vascular cells by interleukin-1, Science, 229, 174, 10.1126/science.2409598 Breviario, 1990, Interleukin-1 stimulates prostacyclin production by cultured human endothelial cells by increasing arachidonic acid mobilization and conversion, Arteriosclerosis, 10, 129, 10.1161/01.ATV.10.1.129 Tracey, 1987, Anti-cachetin TNF monoclonal antibodies prevent septic shock during lethal bacteraemia, Nature, 330, 662, 10.1038/330662a0 Maier, 1990, Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells, J Biol Chem, 265, 10805, 10.1016/S0021-9258(19)38515-1 Kawakami, 1986, Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells, Biochem Biophys Res Commun, 141, 482, 10.1016/S0006-291X(86)80198-X Masferrer, 1990, Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice, J Clin Invest, 86, 1375, 10.1172/JCI114850 Masferrer, 1992, Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme, 89, 3917 Szabó, 1993, Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock, Br J Pharmacol, 108, 786, 10.1111/j.1476-5381.1993.tb12879.x Szabó, 1993, Nifedipine inhibits the induction of nitric oxide synthase by bacterial lipopolysac charide, J Pharmacol Exp Ther, 265, 674 Szabó, 1993, Inhibition of the production of nitric oxide and vasodilator prostaglandins attenuates the cardiovascular response to bacterial endotoxin in adrenalectomised rats, 253, 233 Thiemermann, 1994, The role of arginine: nitric oxide pathway in circulatory shock, Adv Pharmacol, 28, 45, 10.1016/S1054-3589(08)60493-7 Ross, 1986, The pathogenesis of atherosclerosis—an update, N Engl J Med, 314, 488, 10.1056/NEJM198602203140806 Raines, 1993, Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis, Br Heart J, 69, S30, 10.1136/hrt.69.1_Suppl.S30 Gryglewski, 1976, Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides, Prostaglandins, 12, 685, 10.1016/0090-6980(76)90047-2 Moncada, 1976, A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation, Prostaglandins, 12, 715, 10.1016/0090-6980(76)90048-4 Salmon, 1978, Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes, Biochim Biophys Acta, 23, 250, 10.1016/0005-2744(78)90028-1 Glavind, 1952, Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta, Acta Pathol Microbiol Scand, 30, 1, 10.1111/j.1699-0463.1952.tb00157.x TF, 1972 Mickel, 1974, The effect of peroxidized arachidonic acid upon human platelet aggregation, Lipids, 9, 68, 10.1007/BF02532127 Dembinska-Kiec, 1977, The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbit, Prostaglandins, 14, 1025, 10.1016/0090-6980(77)90282-9 D'Angelo, 1978, Defective fibrinolytic and prostacyclin like activity in human atheromatous plaques, Thromb Haemost, 39, 535, 10.1055/s-0038-1646719 Beetens, 1986, Biphasic response of intimal prostacyclin production during the development of experimental atherosclerosis, Prostaglandins, 32, 319, 10.1016/0090-6980(86)90002-X Tremoli, 1982, Increased platelet aggregability is associated with increased prostacyclin production by vessel walls in hypercholesterolemic rabbits, Prostaglandins, 24, 397, 10.1016/0090-6980(82)90166-6 FitzGerald, 1984, Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation, N Engl J Med, 310, 1065, 10.1056/NEJM198404263101701 Mitchell, 1993, Regulation of prostacyclin synthesis by the release of endogenous nitric oxide in response to bacterial lipopolysaccharide, Br J Pharmacol, 109, 4P Sinzinger, 1979, Prostacyclin generation in atherosclerotic arteries, Lancet, ii, 469, 10.1016/S0140-6736(79)91520-4 Eldor, 1982, Diet-induced hypercholesterolemia inhibits the recovery of prostacyclin production by injured rabbit aorta, Am J Pathol, 107, 186 Marks, 1962, Critical appraisal of the therapeutic value of α-tocopherol, Vitam Horn, 20, 573, 10.1016/S0083-6729(08)60738-4 Boyd, 1963, Treatment of intermittent claudication. A reappraisal of the value of α-tocopherol, Angiology, 14, 198, 10.1177/000331976301400409 Haeger, 1968, The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and anti-prothrombin (dicoumarol), Vasc Dis, 5, 199 Ferns, 1993, Vitamin E—the evidence for an anti-atherogenic role, Artery, 20, 61 Willis, 1987, Effects of prostacyclin and orally stable mimetic agent RS-93427-007 on basic mechanisms of atherogenesis, Lancet, ii, 682 Hajjar, 1985, Prostaglandins and cyclic nucleotides: modulators of arterial cholesterol metabolism, Biochem Pharmacol, 34, 295, 10.1016/0006-2952(85)90034-6 Moncada, 1982, Eighth Gaddum Memorial Lecture, 76, 3 Vane, 1982, Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981, 95, 3P Peatfield, 1981, The effect of infused prostacyclin in migraine and cluster headache, Headache, 21, 190, 10.1111/j.1526-4610.1981.hed2105190.x Bennett, 1981, Use of prostacyclin in cardiopulmonary bypass in man, 201 Bunting, 1981, Cardiopulmonary bypass in man: effects of prostacyclin, 181 Chelly, 1981, Hemodynamic effects of prostacyclin infusion after coronary bypass, 209 Radegran, 1981, Effects of prostacyclin during cardiopulmonary bypass in man, Scand J Thorac Cardiovasc Surg, 15, 263, 10.3109/14017438109100584 Walker, 1981, Prostacyclin in cardiopulmonary bypass surgery, 195 Longmore, 1981, Prostacyclin administration during cardiopulmonary bypass in man, Lancet, i, 800, 10.1016/S0140-6736(81)92680-5 Nobak, 1980, Prostacyclin: a potent vasodilator during anaesthesia and cardiac surgery in man, Circulation, 62, 1242 Higenbottam, 1987, The place of prostacyclin in the clinical management of primary pulmonary hypertension, Am Rev Respir Dis, 136, 782, 10.1164/ajrccm/136.3.782 Long, 1987, Prostacyclin and PGE1 treatment of pulmonary hypertension, Am Rev Respir Dis, 136, 773, 10.1164/ajrccm/136.3.773 Yazdani Butt, 1993, Prostaglandins and primary pulmonary hypertension, 198 Walmrath, 1993, Aerosolised prostacyclin in adult respiratory distress syndrome, Lancet, 342, 961, 10.1016/0140-6736(93)92004-D Szczeklik, 1979, Successful therapy of advanced arteriosclerosis obliterans with prostacyclin, Lancet, i, 1111, 10.1016/S0140-6736(79)91792-6 Szczeklik, 1981, Treatment of vascular disease with prostacyclin, 159 Virgolini, 1990, A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease, Prostaglandins, 39, 657, 10.1016/0090-6980(90)90025-Q Virgolini, 1991, Intravenous prostacyclin (PGI2) infusion to 108 patients with ischaemic peripheral vascular disease: Phase II-open study, Prostaglandins, 42, 9, 10.1016/0090-6980(91)90089-X Sinzinger, 1993, Prostaglandins in ischaemic peripheral vascular disease, 209 Dowd, 1982, Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2), Br J Dermatol, 106, 81, 10.1111/j.1365-2133.1982.tb00905.x Belch, 1981, Successful treatment of Raynaud's syndrome with prostacyclin, Thromb Haemost, 45, 255, 10.1055/s-0038-1650182 Belch, 1983, Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome, Lancet, i, 313, 10.1016/S0140-6736(83)91624-0 Belch, 1993, Prostaglandins in Raynaud's phenomenon, 219 Yui, 1982, Prostacyclin therapy in patients with congestive heart failure, Am J Cardiol, 50, 320, 10.1016/0002-9149(82)90183-7 Gheorghiade, 1992, Multicentre, randomized trial of epoprostenol in patients with severe heart failure. (Abstr), J Am Coll Cardiol, 19, 216A Watson, 1991, Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon, Ann Rheum Dis, 50, 359, 10.1136/ard.50.6.359 Torley, 1991, A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases, Ann Rheum Dis, 50, 800, 10.1136/ard.50.11.800 Sakaguchi, 1990, Effect of beraprost sodium (PGI2 derivative) in Raynaud's disease or syndrome. A comparative double blind study with placebo, Clin Res, 67, 234 Sakaguchi, 1990, Effect of beraprost sodium (PGI2 derivative) in chronic arterial occlusive disease. A comparative double blind study with ticlopidine hydrochloride, Clin Res, 67, 575 Schirner, 1992, Antimetastatic potential of the stable prostacyclin analogue cicaprost, 247